Finally, agonists for A3AR including CF102 are currently under clinical trials for several diseases including hepatocellular carcinoma and rheumatoid arthritis16, 29, 30, whereas it would be necessary to discover compounds that activate TMIGD3 i1 signalling. Here, ADORA3 is linked to hepatocellular carcinoma.